The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma
Open accessAbstract
Metastatic neuroblastoma is a poor-prognosis malignancy arising during childhood that overexpresses the L1-cell adhesion molecule (CD171). We have previously described a tumor L1-cell adhesion molecule-specific, single chain antibody-derived, chimeric antigen receptor designated CE7R for re-directing the antigen-specific effector functioning of cytolytic T lymphocytes. Here, we report on the feasibility of isolating, and the safety of infusing, autologous CD8(+) cytolytic T lymphocyte clones co-expressing CE7R and the selection-suicide expression enzyme HyTK in children with recurrent/refractory neuroblastoma. The cytolytic T lymphocyte products were derived from peripheral blood mononuclear cells that were subjected to polyclonal activation, plasmid vector electrotransfer, limiting dilution hygromycin selection, and expansion to numbers sufficient for adoptive transfer. In total, 12 infusions (nine at 10(8) cells/m(2), three at 10(9) cells/m(2)) were administered to six patients. No overt toxicities to tissues known to express L1-cell adhesion molecule (e.g., central nervous system, adrenal medulla, and sympathetic ganglia) were observed. The persistence of cytolytic T lymphocyte clones in the circulation, measured by vector-specific quantitative polymerase chain reaction, was short (1-7 days) in patients with bulky disease, but significantly longer (42 days) in a patient with a limited disease burden. This first-in-humans pilot study sets the stage for clinical trials employing adoptive transfer in the context of minimal residual disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
A distinct “side population” of cells with high drug efflux capacity in human tumor cells
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., & Brenner, M. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400067101 · Cited by 1,280
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,201
Stem Cells and Cancer: Two Faces of Eve
Clarke, M. F., & Fuller, M. (2006) · Cell · doi:10.1016/j.cell.2006.03.011 · Cited by 905
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Mechtersheimer, S., Gutwein, P., Agmon-Levin, N., Stoeck, A., Oleszewski, M., Riedle, S., Postina, R., Fahrenholz, F., Fogel, M., Lemmon, V., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200101099 · Cited by 391
Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 368
Self-citationRosenberg, S. A., & Dudley, M. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405730101 · Cited by 364
Gavert, N., Conacci-Sorrell, M., Gast, D., Schneider, A., Altevogt, P., Brabletz, T., & Ben-Ze'ev, A. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200408051 · Cited by 359
Berger, C., Flowers, M. E., Warren, E. H., & Riddell, S. R. (2006) · Blood · doi:10.1182/blood-2005-08-3503 · Cited by 334
Fogel, M., Gutwein, P., Mechtersheimer, S., Riedle, S., Stoeck, A., Smirnov, A., Edler, L., Ben-Arie, A., Huszar, M., & Altevogt, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14342-5 · Cited by 284
Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2
Metelitsa, L. S., Wu, H.-W., Wang, H., Yang, Y., Warsi, Z., Asgharzadeh, S., Groshen, S., Wilson, S. B., & Seeger, R. C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031462 · Cited by 261
Montgomery, A. M., Becker, J. C., Siu, C. H., Lemmon, V. P., Cheresh, D. A., Pancook, J. D., Zhao, X., & Reisfeld, R. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.132.3.475 · Cited by 230
Calvo, A., Xiao, N., Kang, J., Best, C. J. M., Leiva, I. M., Emmert‐Buck, M. R., Jorcyk, C. L., & Green, J. E. (2002) · PubMed · Cited by 177
Arlt, M., Novak‐Hofer, I., Gast, D., Gschwend, V., Moldenhauer, G., Grünberg, J., Honer, M., Schubiger, P. A., Altevogt, P., & Krüger, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1818 · Cited by 170
Thies, A., Schachner, M., Moll, I., Berger, J., Schulze, H.-J., Brunner, G., & Schumacher, U. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00105-3 · Cited by 164
Silletti, S., Yebra, M., Perez, B., Cirulli, V., McMahon, M., & Montgomery, A. M. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404075200 · Cited by 140
Allory, Y., Matsuoka, Y., Bazille, C., Christensen, E., Ronco, P. M., & Dêbiec, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1190.11.3 · Cited by 115
Izumoto, S., Ohnishi, T., Arita, N., Hiraga, S., Taki, T., & Hayakawa, T. (1996) · PubMed · Cited by 97
Wang, J., Press, O. W., Lindgren, C. G., Greenberg, P. D., Riddell, S. R., Qian, X., Laugen, C., Raubitschek, A. A., Forman, S. J., & Jensen, M. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.011 · Cited by 81
Self-citationIdentification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens
Euer, N., Kaul, S., Deißler, H., Möbus, V. J., Zeillinger, R., & Weidle, U. H. (2005) · Oncology Reports · doi:10.3892/or.13.3.375 · Cited by 58
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Metadata
- Authors
- Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., & Jensen, M. C.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 15
- Issue
- 4
- Pages
- 825-833
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2068890283
- Cited by
- 603
- References
- 22
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.